{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:38:29Z","timestamp":1791236309383,"version":"4.1.0"},"reference-count":233,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The intestinal immune compartment plays a central role in HIV pathogenesis, serving as an early site for viral replication and a significant reservoir for latent infection. Despite the success of antiretroviral therapy (ART) in suppressing plasma viremia, HIV persists indefinitely in latently infected cells, commonly found in the intestinal tract due to its unique immunological and structural environment. Targeting HIV-infected cells that persist in the intestinal tract is an important consideration for therapeutic strategies and is also important when considering an HIV cure. This review describes the therapeutic approaches aimed at addressing HIV persistence in the intestinal tract, or gut. We provide a brief overview of mechanisms underlying reservoir formation and maintenance, discuss the challenges posed by gut-specific factors, and examine emerging strategies, including latency reversal agents, immune modulation, gut-targeted ART, and novel delivery systems. This review will focus on contemporary advances in knowledge in this space, gaps in the literature and areas for future research focus.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1650852","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:31:46Z","timestamp":1758173506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["HIV and the gut: implications for HIV persistence, immune dysfunction and cure strategies"],"prefix":"10.3389","volume":"16","author":[{"given":"Jillian S. Y.","family":"Lau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon R.","family":"Lewin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushama","family":"Telwatte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1086\/527324","article-title":"Persistence of HIV in gut-associated lymphoid tissue despite long-term antiretroviral therapy","volume":"197","author":"Chun","year":"2008","journal-title":"J Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1086\/317625","article-title":"Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines","volume":"182","author":"Olsson","year":"2000","journal-title":"J Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200008180-00011","article-title":"Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue","volume":"14","author":"Anton","year":"2000","journal-title":"AIDS"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.18.8390-8399.2001","article-title":"A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection","volume":"75","author":"Poles","year":"2001","journal-title":"J Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e3182986ff8","article-title":"Antiretroviral pharmacology in mucosal tissues","author":"Thompson","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000301","article-title":"GSK1265744 pharmacokinetics in plasma and tissue after single-dose long-acting injectable administration in healthy subjects","volume":"67","author":"Spreen","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(16)30113-8","article-title":"Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment","volume":"3","author":"McGowan","year":"2016","journal-title":"Lancet HIV"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaf117","article-title":"Impact of switching to long-acting injectable cabotegravir plus rilpivirine on rectal HIV-1 RNA shedding and implications for transmission risk","volume":"231","author":"Masia","year":"2025","journal-title":"J Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nri1057","article-title":"Anatomical basis of tolerance and immunity to intestinal antigens","volume":"3","author":"Mowat","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nri3738","article-title":"Regional specialization within the intestinal immune system","volume":"14","author":"Mowat","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/s41385-021-00389-4","article-title":"Human gut-associated lymphoid tissues (GALT); diversity, structure, and function","volume":"14","author":"Morbe","year":"2021","journal-title":"Mucosal Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12821","article-title":"The immunology of the vermiform appendix: a review of the literature","volume":"186","author":"Kooij","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e318162c3ec","article-title":"The rectal tonsil: a reactive lymphoid proliferation that may mimic lymphoma","volume":"32","author":"Farris","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i8.2563","article-title":"Rectal tonsil: a case report and literature review","volume":"21","author":"Hong","year":"2015","journal-title":"World J Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/gut.37.4.524","article-title":"Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood","volume":"37","author":"Schneider","year":"1995","journal-title":"Berlin Diarrhea\/Wasting Syndrome Study Group Gut"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1997.236-ce1111.x","article-title":"Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection","volume":"107","author":"Clayton","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20041196","article-title":"Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract","volume":"200","author":"Mehandru","year":"2004","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040874","article-title":"CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract","volume":"200","author":"Brenchley","year":"2004","journal-title":"J Exp Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.8.6646-6656.1998","article-title":"Gastrointestinal T lymphocytes retain high potential for cytokine responses but have severe CD4(+) T-cell depletion at all stages of simian immunodeficiency virus infection compared to peripheral lymphocytes","volume":"72","author":"Smit-McBride","year":"1998","journal-title":"J Virol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70014-4","article-title":"Rapid mucosal CD4(+) T-cell depletion and enteropathy in simian immunodeficiency virus-infected rhesus macaques","volume":"116","author":"Kewenig","year":"1999","journal-title":"Gastroenterology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1086\/323615","article-title":"Early immunologic events in mucosal and systemic lymphoid tissues after intrarectal inoculation with simian immunodeficiency virus","volume":"184","author":"Vajdy","year":"2001","journal-title":"J Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.21.11708-11717.2003","article-title":"Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy","volume":"77","author":"Guadalupe","year":"2003","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/368386","article-title":"Vaginal CD4+ T cells express high levels of CCR5 and are rapidly depleted in simian immunodeficiency virus infection","volume":"187","author":"Veazey","year":"2003","journal-title":"J Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e1004543","DOI":"10.1371\/journal.ppat.1004543","article-title":"Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation","volume":"10","author":"Schuetz","year":"2014","journal-title":"PloS Pathog"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4172\/2155-6113.1000302","article-title":"Th17 cells coordinate with th22 cells in maintaining homeostasis of intestinal tissues and both are depleted in SIV-infected macaques","volume":"5","author":"Xu","year":"2014","journal-title":"J AIDS Clin Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1086\/314660","article-title":"Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage","volume":"179","author":"Giorgi","year":"1999","journal-title":"J Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nm1380","article-title":"Pathogenesis of HIV infection: what the virus spares is as important as what it destroys","volume":"12","author":"Grossman","year":"2006","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(91)90092-8","article-title":"Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis","volume":"12","author":"Ameisen","year":"1991","journal-title":"Immunol Today"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1000852","DOI":"10.1371\/journal.ppat.1000852","article-title":"Exposure to HIV-1 directly impairs mucosal epithelial barrier integrity allowing microbial translocation","volume":"6","author":"Nazli","year":"2010","journal-title":"PloS Pathog"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-014-0666-5","article-title":"Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies","volume":"42","author":"Assimakopoulos","year":"2014","journal-title":"Infection"},{"key":"B32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.immuni.2020.02.001","article-title":"Immune profiling of human gut-associated lymphoid tissue identifies a role for isolated lymphoid follicles in priming of region-specific immunity","volume":"52","author":"Fenton","year":"2020","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0110-8","article-title":"Microanatomical dissection of human intestinal T-cell immunity reveals site-specific changes in gut-associated lymphoid tissues over life","volume":"12","author":"Senda","year":"2019","journal-title":"Mucosal Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e0121290","DOI":"10.1371\/journal.pone.0121290","article-title":"Site-specific differences in T cell frequencies and phenotypes in the blood and gut of HIV-uninfected and ART-treated HIV+ adults","volume":"10","author":"Yukl","year":"2015","journal-title":"PloS One"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2101102","article-title":"Common and divergent features of T cells from blood, gut, and genital tract of antiretroviral therapy-treated HIV(+) women","volume":"208","author":"Xie","year":"2022","journal-title":"J Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1007357","DOI":"10.1371\/journal.ppat.1007357","article-title":"Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency","volume":"14","author":"Telwatte","year":"2018","journal-title":"PloS Pathog"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000166","article-title":"A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells","volume":"28","author":"Yukl","year":"2014","journal-title":"AIDS"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e25738","DOI":"10.1002\/jia2.25738","article-title":"Tissue-specific differences in HIV DNA levels and mechanisms that govern HIV transcription in blood, gut, genital tract and liver in ART-treated women","volume":"24","author":"Moron-Lopez","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002684","article-title":"Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents","volume":"34","author":"Telwatte","year":"2020","journal-title":"AIDS"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1249288","DOI":"10.1126\/science.1249288","article-title":"Microbiota-dependent crosstalk between macrophages and ILC3 promotes intestinal homeostasis","volume":"343","author":"Mortha","year":"2014","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1198469","article-title":"Induction of colonic regulatory T cells by indigenous Clostridium species","volume":"331","author":"Atarashi","year":"2011","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"103114","DOI":"10.1016\/j.jaut.2023.103114","article-title":"The gut ecosystem and immune tolerance","volume":"141","author":"Shao","year":"2023","journal-title":"J Autoimmun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2017.0153","article-title":"Differentiating immune cell targets in gut-associated lymphoid tissue for HIV cure","volume":"33","author":"Khan","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-020-0286-6","article-title":"Th22 cells are efficiently recruited in the gut by CCL28 as an alternative to CCL20 but do not compensate for the loss of Th17 cells in treated HIV-1-infected individuals","volume":"14","author":"Nayrac","year":"2021","journal-title":"Mucosal Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105927118","article-title":"Th17 cell master transcription factor RORC2 regulates HIV-1 gene expression and viral outgrowth","volume":"118","author":"Wiche Salinas","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2025","article-title":"Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22","volume":"12","author":"Sonnenberg","year":"2011","journal-title":"Nat Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz509","article-title":"Human immunodeficiency virus (HIV)-infected CCR6+ Rectal CD4+ T cells and HIV persistence on antiretroviral therapy","volume":"221","author":"Anderson","year":"2020","journal-title":"J Infect Dis"},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12977-016-0293-6","article-title":"New insights into the heterogeneity of Th17 subsets contributing to HIV-1 persistence during antiretroviral therapy","volume":"13","author":"Wacleche","year":"2016","journal-title":"Retrovirology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1089\/vim.2006.0063","article-title":"Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection","volume":"20","author":"Maek","year":"2007","journal-title":"Viral Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090858","article-title":"Dynamic T cell migration program provides resident memory within intestinal epithelium","volume":"207","author":"Masopust","year":"2010","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08466-x","article-title":"Tissue-resident memory CD8 T cell diversity is spatiotemporally imprinted","volume":"639","author":"Reina-Campos","year":"2025","journal-title":"Nature"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/372190a0","article-title":"Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin","volume":"372","author":"Cepek","year":"1994","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.08.019","article-title":"Transforming growth factor-beta signaling controls the formation and maintenance of gut-resident memory T cells by regulating migration and retention","volume":"39","author":"Zhang","year":"2013","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.078","article-title":"Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites","volume":"20","author":"Kumar","year":"2017","journal-title":"Cell Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01331-20","article-title":"Shared mechanisms govern HIV transcriptional suppression in circulating CD103(+) and gut CD4(+) T cells","volume":"95","author":"Yukl","year":"2020","journal-title":"J Virol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad2035","article-title":"Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes","volume":"352","author":"Mackay","year":"2016","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.1.209","article-title":"V7 (CD101) ligation inhibits TCR\/CD3-induced IL-2 production by blocking Ca2+ flux and nuclear factor of activated T cell nuclear translocation","volume":"161","author":"Soares","year":"1998","journal-title":"J Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.151.9.5031","article-title":"Elevated IFN-gamma and decreased IL-2 gene expression are associated with HIV infection","volume":"151","author":"Fan","year":"1993","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.144.2.480","article-title":"Infection with HIV is associated with elevated IL-6 levels and production","volume":"144","author":"Breen","year":"1990","journal-title":"J Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"32ra6","DOI":"10.1126\/scitranslmed.3000632","article-title":"Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease","volume":"2","author":"Favre","year":"2010","journal-title":"Sci Transl Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000174","article-title":"Elevated IP10 levels are associated with immune activation and low CD4(+) T-cell counts in HIV controller patients","volume":"28","author":"Noel","year":"2014","journal-title":"AIDS"},{"key":"B63","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1128\/JVI.01739-06","article-title":"Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection","volume":"81","author":"Mehandru","year":"2007","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283471d10","article-title":"Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count","volume":"25","author":"Marchetti","year":"2011","journal-title":"AIDS"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0183372","DOI":"10.1371\/journal.pone.0183372","article-title":"Microbial translocation is correlated with HIV evolution in HIV-HCV co-infected patients","volume":"12","author":"Tudesq","year":"2017","journal-title":"PloS One"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001771","article-title":"A prospective study of serum microbial translocation biomarkers and risk of AIDS-related non-Hodgkin lymphoma","volume":"32","author":"Epeldegui","year":"2018","journal-title":"AIDS"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz212","article-title":"Circulating (1\u2013>3)-beta-D-glucan is associated with immune activation during human immunodeficiency virus infection","volume":"70","author":"Mehraj","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1038\/s41467-018-05199-0","article-title":"Molecular architecture of fungal cell walls revealed by solid-state NMR","volume":"9","author":"Kang","year":"2018","journal-title":"Nat Commun"},{"key":"B69","doi-asserted-by":"publisher","first-page":"43741","DOI":"10.1038\/srep43741","article-title":"Fecal Bacterial Communities in treated HIV infected individuals on two antiretroviral regimens","volume":"7","author":"Pinto-Cardoso","year":"2017","journal-title":"Sci Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz423","article-title":"Plasma levels of C-type lectin REG3alpha and gut damage in people with human immunodeficiency virus","volume":"221","author":"Isnard","year":"2020","journal-title":"J Infect Dis"},{"key":"B71","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1471-2334-13-203","article-title":"Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors","volume":"13","author":"Cassol","year":"2013","journal-title":"BMC Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3205\/id000018","article-title":"Correlation of (1\u2013>3)-beta-D-glucan with other inflammation markers in chronically HIV infected persons on suppressive antiretroviral therapy","volume":"3","author":"Hoenigl","year":"2015","journal-title":"GMS Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1001","article-title":"Cytomegalovirus seropositivity is associated with increased microbial translocation in people living with human immunodeficiency virus and uninfected controls","volume":"71","author":"Ramendra","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B74","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-023-01906-5","article-title":"A germ-free humanized mouse model shows the contribution of resident microbiota to human-specific pathogen infection","volume":"42","author":"Wahl","year":"2024","journal-title":"Nat Biotechnol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40168-022-01247-6","article-title":"Gut microbiome signatures linked to HIV-1 reservoir size and viremia control","volume":"10","author":"Borgognone","year":"2022","journal-title":"Microbiome"},{"key":"B77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12977-024-00655-w","article-title":"Exploring potential associations between the human microbiota and reservoir of latent HIV","volume":"21","author":"Marin-Sanchez","year":"2024","journal-title":"Retrovirology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/s41467-021-21472-1","article-title":"Fecal microbiota transplantation in HIV: A pilot placebo-controlled study","volume":"12","author":"Serrano-Villar","year":"2021","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12981-016-0103-1","article-title":"Gut barrier structure, mucosal immunity and intestinal microbiota in the pathogenesis and treatment of HIV infection","volume":"13","author":"Tincati","year":"2016","journal-title":"AIDS Res Ther"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw258","article-title":"Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression","author":"Mudd","year":"2016","journal-title":"J Infect Dis"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318249111","article-title":"Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues","volume":"111","author":"Fletcher","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002287","article-title":"Antiretroviral therapy concentrations differ in gut vs. Lymph node tissues and are associated with HIV viral transcription by a novel RT-ddPCR assay","volume":"83","author":"Lee","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003201","article-title":"Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression","volume":"36","author":"Fletcher","year":"2022","journal-title":"AIDS"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/nature16933","article-title":"Persistent HIV-1 replication maintains the tissue reservoir during therapy","volume":"530","author":"Lorenzo-Redondo","year":"2016","journal-title":"Nature"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav2045","article-title":"No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication","volume":"5","author":"Bozzi","year":"2019","journal-title":"Sci Adv"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1172\/JCI126714","article-title":"HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy","volume":"129","author":"McManus","year":"2019","journal-title":"J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0253","article-title":"HIV persistence in gut-associated lymphoid tissues: pharmacological challenges and opportunities","volume":"33","author":"Thompson","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B90","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \u201cKill\u201d into \u201cShock and kill\u201d: strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1111\/jmp.12613","article-title":"The role of latency reversal in HIV cure strategies","volume":"51","author":"Tanaka","year":"2022","journal-title":"J Med Primatol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coviro.2019.03.004","article-title":"Between a shock and a hard place: challenges and developments in HIV latency reversal","volume":"38","author":"Zerbato","year":"2019","journal-title":"Curr Opin Virol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03060","article-title":"Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs","volume":"10","author":"Ait-Ammar","year":"2019","journal-title":"Front Microbiol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix201","article-title":"Short-course toll-like receptor 9 agonist treatment impacts innate immunity and plasma viremia in individuals with human immunodeficiency virus infection","volume":"64","author":"Vibholm","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B96","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/1742-4690-10-119","article-title":"Reactivation of latent HIV-1 in central memory CD4(+) T cells through TLR-1\/2 stimulation","volume":"10","author":"Novis","year":"2013","journal-title":"Retrovirology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"e0081621","DOI":"10.1128\/JVI.00816-21","article-title":"TLR1\/2 agonist enhances reversal of HIV-1 latency and promotes NK cell-induced suppression of HIV-1-infected autologous CD4(+) T cells","volume":"95","author":"Duan","year":"2021","journal-title":"J Virol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"104549","DOI":"10.1016\/j.ebiom.2023.104549","article-title":"Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes","volume":"91","author":"Jimenez-Leon","year":"2023","journal-title":"EBioMedicine"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2017.59","article-title":"The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon","volume":"11","author":"Krarup","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3071","article-title":"The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy","volume":"13","author":"SenGupta","year":"2021","journal-title":"Sci Transl Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2023.1033448","article-title":"Novel TLR7\/8 agonists promote activation of HIV-1 latent reservoirs and human T and NK cells","volume":"14","author":"Li","year":"2023","journal-title":"Front Microbiol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"120605","DOI":"10.1155\/2015\/120605","article-title":"Administration of panobinostat is associated with increased IL-17A mRNA in the intestinal epithelium of HIV-1 patients","volume":"2015","author":"Bjerg Christensen","year":"2015","journal-title":"Mediators Inflamm"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e1004473","DOI":"10.1371\/journal.ppat.1004473","article-title":"Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy","volume":"10","author":"Elliott","year":"2014","journal-title":"PloS Pathog"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120633","article-title":"Structure-guided drug design identifies a BRD4-selective small molecule that suppresses HIV","volume":"129","author":"Niu","year":"2019","journal-title":"J Clin Invest"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.248021","article-title":"Impaired infectivity of ritonavir-resistant HIV is rescued by heat shock protein 90AB1","volume":"286","author":"Joshi","year":"2011","journal-title":"J Biol Chem"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320178111","article-title":"Heat shock protein 90 controls HIV-1 reactivation from latency","volume":"111","author":"Anderson","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B108","doi-asserted-by":"publisher","first-page":"28896","DOI":"10.1038\/srep28896","article-title":"Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a HSP90-dependent manner","volume":"6","author":"Kim","year":"2016","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.370","article-title":"Rational design of small-molecule inhibitors of the LEDGF\/p75-integrase interaction and HIV replication","volume":"6","author":"Christ","year":"2010","journal-title":"Nat Chem Biol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00717-12","article-title":"Small-molecule inhibitors of the LEDGF\/p75 binding site of integrase block HIV replication and modulate integrase multimerization","volume":"56","author":"Christ","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e1006740","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PloS Pathog"},{"key":"B113","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13072-019-0267-8","article-title":"Tat inhibition by didehydro-Cortistatin A promotes heterochromatin formation at the HIV-1 long terminal repeat","volume":"12","author":"Li","year":"2019","journal-title":"Epigenet Chromatin"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.09.080","article-title":"In vivo suppression of HIV rebound by didehydro-cortistatin A, a \u201cBlock-and-lock\u201d Strategy for HIV-1 treatment","volume":"21","author":"Kessing","year":"2017","journal-title":"Cell Rep"},{"key":"B115","first-page":"97","article-title":"Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue","volume":"151","author":"Briskin","year":"1997","journal-title":"Am J Pathol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.2.517","article-title":"Expression and function of the MAdCAM-1 receptor, integrin alpha 4 beta 7, on human leukocytes","volume":"153","author":"Erle","year":"1994","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/ni1566","article-title":"HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells","volume":"9","author":"Arthos","year":"2008","journal-title":"Nat Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0911796106","article-title":"The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1","volume":"106","author":"Cicala","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2009.90","article-title":"Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection","volume":"2","author":"Kader","year":"2009","journal-title":"Mucosal Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2009.104","article-title":"Monitoring alpha4beta7 integrin expression on circulating CD4+ T cells as a surrogate marker for tracking intestinal CD4+ T-cell loss in SIV infection","volume":"2","author":"Wang","year":"2009","journal-title":"Mucosal Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31829f6e1a","article-title":"The frequency of alpha(4)beta(7)(high) memory CD4(+) T cells correlates with susceptibility to rectal simian immunodeficiency virus infection","volume":"64","author":"Martinelli","year":"2013","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau4711","article-title":"Anti-alpha4beta7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals","volume":"10","author":"Uzzan","year":"2018","journal-title":"Sci Transl Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1084\/jem.187.6.949","article-title":"The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy","volume":"187","author":"Tenner-Racz","year":"1998","journal-title":"J Exp Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1172\/JCI63039","article-title":"CD4 T follicular helper cell dynamics during SIV infection","volume":"122","author":"Petrovas","year":"2012","journal-title":"J Clin Invest"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5289.985","article-title":"Quantitative image analysis of HIV-1 infection in lymphoid tissue","volume":"274","author":"Haase","year":"1996","journal-title":"Science"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3781","article-title":"B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers","volume":"21","author":"Fukazawa","year":"2015","journal-title":"Nat Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1126\/science.aag1276","article-title":"Sustained virologic control in SIV+ macaques after antiretroviral and alpha4beta7 antibody therapy","volume":"354","author":"Byrareddy","year":"2016","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1126\/science.aax2933","article-title":"Editorial expression of concern","volume":"363","author":"Berg","year":"2019","journal-title":"Science"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw8562","article-title":"Lack of therapeutic efficacy of an antibody to alpha(4)beta(7) in SIVmac251-infected rhesus macaques","volume":"365","author":"Abbink","year":"2019","journal-title":"Science"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax3447","article-title":"An open-label phase 1 clinical trial of the anti-alpha(4)beta(7) monoclonal antibody vedolizumab in HIV-infected individuals","volume":"11","author":"Sneller","year":"2019","journal-title":"Sci Transl Med"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182312","article-title":"Vedolizumab and ART in recent HIV-1 infection unveil the role of alpha4beta7 in reservoir size","volume":"9","author":"Jimenez-Leon","year":"2024","journal-title":"JCI Insight"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1172\/JCI59011","article-title":"Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals","volume":"122","author":"Mavigner","year":"2012","journal-title":"J Clin Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy060","article-title":"Gut-selective integrin-targeted therapies for inflammatory bowel disease","volume":"12","author":"Lamb","year":"2018","journal-title":"J Crohns Colitis"},{"key":"B134","doi-asserted-by":"publisher","first-page":"103840","DOI":"10.1016\/j.ebiom.2022.103840","article-title":"Immune checkpoint blockade in HIV","volume":"76","author":"Gubser","year":"2022","journal-title":"EBioMedicine"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1901191","article-title":"Combination immune checkpoint blockade to reverse HIV latency","volume":"204","author":"Van der Sluis","year":"2020","journal-title":"J Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002716","article-title":"Suspected immune-related adverse events with an anti-PD-1 inhibitor in otherwise healthy people with HIV","volume":"87","author":"Gay","year":"2021","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B137","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","article-title":"Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial","volume":"28","author":"Miller","year":"2022","journal-title":"Nat Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00235-18","article-title":"Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo","volume":"92","author":"Garrido","year":"2018","journal-title":"J Virol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","article-title":"The human IL-15 superagonist ALT-803 directs SIV-specific CD8(+) T cells into B-cell follicles","volume":"2","author":"Webb","year":"2018","journal-title":"Blood Adv"},{"key":"B140","doi-asserted-by":"publisher","first-page":"e1008339","DOI":"10.1371\/journal.ppat.1008339","article-title":"The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques","volume":"16","author":"Webb","year":"2020","journal-title":"PloS Pathog"},{"key":"B141","doi-asserted-by":"publisher","first-page":"100082","DOI":"10.1016\/j.jve.2022.100082","article-title":"Combination strategies to durably suppress HIV-1: Soluble T cell receptors","volume":"8","author":"Wallace","year":"2022","journal-title":"J Virus Erad"},{"key":"B142","doi-asserted-by":"publisher","first-page":"e71879","DOI":"10.1371\/journal.pone.0071879","article-title":"Gag-positive reservoir cells are susceptible to HIV-specific cytotoxic T lymphocyte mediated clearance in vitro and can be detected in vivo [corrected","volume":"8","author":"Graf","year":"2013","journal-title":"PloS One"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab121","article-title":"Gag p24 is a marker of human immunodeficiency virus expression in tissues and correlates with immune response","volume":"224","author":"Wu","year":"2021","journal-title":"J Infect Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000528","article-title":"Role of cytokine agonists and immune checkpoint inhibitors toward HIV remission","volume":"14","author":"Hoang","year":"2019","journal-title":"Curr Opin HIV AIDS"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.75","article-title":"IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-treated, SIV-infected macaques","volume":"9","author":"Ortiz","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-025-00886-9","article-title":"MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy","volume":"32","author":"Ibrahim","year":"2025","journal-title":"Cancer Gene Ther"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.043","article-title":"Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice","volume":"158","author":"Halper-Stromberg","year":"2014","journal-title":"Cell"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1","volume":"352","author":"Lu","year":"2016","journal-title":"vivo Sci"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/nature21435","article-title":"Early antibody therapy can induce long-lasting immunity to SHIV","volume":"543","author":"Nishimura","year":"2017","journal-title":"Nature"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01815-1","article-title":"Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial","volume":"28","author":"Julg","year":"2022","journal-title":"Nat Med"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination therapy with anti-HIV-1 antibodies maintains viral suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B153","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1038\/s41467-023-41966-4","article-title":"Mucosal application of the broadly neutralizing antibody 10\u20131074 protects macaques from cell-associated SHIV vaginal exposure","volume":"14","author":"Suphaphiphat","year":"2023","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13063-022-06151-w","article-title":"The RIO trial: rationale, design, and the role of community involvement in a randomised placebo-controlled trial of antiretroviral therapy plus dual long-acting HIV-specific broadly neutralising antibodies (bNAbs) in participants diagnosed with recent HIV infection-study protocol for a two-stage randomised phase II trial","volume":"23","author":"Lee","year":"2022","journal-title":"Trials"},{"key":"B155","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40168-024-01825-w","article-title":"From dysbiosis to defense: harnessing the gut microbiome in HIV\/SIV therapy","volume":"12","author":"Brenchley","year":"2024","journal-title":"Microbiome"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu515","article-title":"Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286","volume":"211","author":"Tenorio","year":"2015","journal-title":"J Infect Dis"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz494","article-title":"Effect of stopping cotrimoxazole preventive therapy on microbial translocation and inflammatory markers among human immunodeficiency virus-infected Ugandan adults on antiretroviral therapy: the COSTOP trial immunology substudy","volume":"222","author":"Kyosiimire-Lugemwa","year":"2020","journal-title":"J Infect Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000468","article-title":"Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial","volume":"68","author":"Villar-Garcia","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.122","article-title":"The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects","volume":"10","author":"Serrano-Villar","year":"2017","journal-title":"Mucosal Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2011.15","article-title":"Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: results of the \u201cCOPA\u201d pilot randomized trial","volume":"4","author":"Gori","year":"2011","journal-title":"Mucosal Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy414","article-title":"Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)","volume":"68","author":"Serrano-Villar","year":"2019","journal-title":"Clin Infect Dis"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072112","article-title":"Effect of a nutritional intervention on the intestinal microbiota of vertically HIV-infected children: the pediabiota study","volume":"12","author":"Sainz","year":"2020","journal-title":"Nutrients"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/nu14050992","article-title":"Targeting the gut microbiota of vertically HIV-infected children to decrease inflammation and immunoactivation: A pilot clinical trial","volume":"14","author":"Sainz","year":"2022","journal-title":"Nutrients"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.840245","article-title":"Lactobacillus spp. for gastrointestinal health: current and future perspectives","volume":"13","author":"Dempsey","year":"2022","journal-title":"Front Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2106516","article-title":"SER-109, an oral microbiome therapy for recurrent clostridioides difficile infection","volume":"386","author":"Feuerstadt","year":"2022","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12879-022-07256-y","article-title":"Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial","volume":"22","author":"Orenstein","year":"2022","journal-title":"BMC Infect Dis"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3390\/nu11071675","article-title":"Vitamin D and phenylbutyrate supplementation does not modulate gut derived immune activation in HIV-1","volume":"11","author":"Missailidis","year":"2019","journal-title":"Nutrients"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001366","article-title":"Low abundance of colonic butyrate-producing bacteria in HIV infection is associated with microbial translocation and immune activation","volume":"31","author":"Dillon","year":"2017","journal-title":"AIDS"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700105","article-title":"Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2","volume":"199","author":"Zheng","year":"2017","journal-title":"J Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1334034","article-title":"Limited engraftment of donor microbiome via one-time fecal microbial transplantation in treated HIV-infected individuals","volume":"8","author":"Vujkovic-Cvijin","year":"2017","journal-title":"Gut Microbes"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v5i1.388","article-title":"Evaluation of six weekly oral fecal microbiota transplants in people with HIV","volume":"5","author":"Utay","year":"2020","journal-title":"Pathog Immun"},{"key":"B172","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s40168-024-01919-5","article-title":"Fecal microbiota transplantation alters the proteomic landscape of inflammation in HIV: identifying bacterial drivers","volume":"12","author":"Diaz-Garcia","year":"2024","journal-title":"Microbiome"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0127","article-title":"Effect of statin use on inflammation and immune activation biomarkers in HIV-infected persons on effective antiretroviral therapy","volume":"37","author":"Hussain","year":"2021","journal-title":"AIDS Res Hum Retroviruses"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq115","article-title":"High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: results of a double-blind randomized placebo controlled clinical trial","volume":"203","author":"Ganesan","year":"2011","journal-title":"J Infect Dis"},{"key":"B175","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/QAI.0000000000000478","article-title":"Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy","volume":"68","author":"Funderburg","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"B176","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01186-18","article-title":"P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines interleukin-10 (IL-10) and IL-1beta in a human tonsil explant model","volume":"93","author":"Soare","year":"2019","journal-title":"J Virol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1beta inhibition reduces atherosclerotic inflammation in HIV infection","volume":"72","author":"Hsue","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.101386","article-title":"Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn\u2019s disease","volume":"55","author":"Beltran","year":"2006","journal-title":"Gut"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.043","article-title":"Use of tumor necrosis factor (TNF) inhibitors in patients with HIV\/AIDS","volume":"74","author":"Gallitano","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad199","article-title":"Interleukin 6 blockade with tocilizumab diminishes indices of inflammation that are linked to mortality in treated human immunodeficiency virus infection","volume":"77","author":"Funderburg","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B182","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12974-018-1126-4","article-title":"HIV-1 Tat-induced diarrhea is improved by the PPARalpha agonist, palmitoylethanolamide, by suppressing the activation of enteric glia","volume":"15","author":"Sarnelli","year":"2018","journal-title":"J Neuroinflamm"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2008.07.023","article-title":"PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic epithelial cells","volume":"380","author":"Boisvert","year":"2008","journal-title":"Virology"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S207277","article-title":"The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease","volume":"13","author":"Zhang","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B185","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s12985-014-0214-z","article-title":"E5564 inhibits immunosuppressive cytokine IL-10 induction promoted by HIV-1 Tat protein","volume":"11","author":"Bahraoui","year":"2014","journal-title":"Virol J"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.109.187518","article-title":"Structure and function of HDL mimetics","volume":"30","author":"Navab","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"e00154","DOI":"10.1002\/prp2.154","article-title":"Efficacy of tomato concentrates in mouse models of dyslipidemia and cancer","volume":"3","author":"Chattopadhyay","year":"2015","journal-title":"Pharmacol Res Perspect"},{"key":"B188","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1038\/s41598-018-26755-0","article-title":"Treating the intestine with oral apoA-I mimetic tg6F reduces tumor burden in mouse models of metastatic lung cancer","volume":"8","author":"Chattopadhyay","year":"2018","journal-title":"Sci Rep"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010160","article-title":"ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV","volume":"18","author":"Daskou","year":"2022","journal-title":"PloS Pathog"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.1","article-title":"Unique IL-13Ralpha2-based HIV-1 vaccine strategy to enhance mucosal immunity, CD8(+) T-cell avidity and protective immunity","volume":"6","author":"Ranasinghe","year":"2013","journal-title":"Mucosal Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.133","article-title":"A dendritic cell targeted vaccine induces long-term HIV-specific immunity within the gastrointestinal tract","volume":"9","author":"Ruane","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00255","article-title":"Dendritic cell-targeted vaccines","volume":"5","author":"Cohn","year":"2014","journal-title":"Front Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501243","article-title":"Oral immunization with a recombinant lactococcus lactis-expressing HIV-1 antigen on group A streptococcus pilus induces strong mucosal immunity in the gut","volume":"195","author":"Chamcha","year":"2015","journal-title":"J Immunol"},{"key":"B194","doi-asserted-by":"publisher","first-page":"102372","DOI":"10.1016\/j.omtn.2024.102372","article-title":"The role of mRNA-galsomes and LNPs in enhancing HIV-specific T cell responses across various lymphoid organs","volume":"35","author":"D\u2019Haese","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"B195","doi-asserted-by":"publisher","first-page":"eadr8382","DOI":"10.1126\/science.adr8382","article-title":"Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans","volume":"2025","author":"Willis","year":"2025","journal-title":"Science"},{"key":"B196","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41541-021-00307-6","article-title":"Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates","volume":"6","author":"Saunders","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B197","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm1520","article-title":"CD8+ T-cell responses to different HIV proteins have discordant associations with viral load","volume":"13","author":"Kiepiela","year":"2007","journal-title":"Nat Med"},{"key":"B198","doi-asserted-by":"publisher","first-page":"110514","DOI":"10.1016\/j.celrep.2022.110514","article-title":"mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice","volume":"38","author":"Mu","year":"2022","journal-title":"Cell Rep"},{"key":"B199","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030360","article-title":"Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth","volume":"8","author":"Moyo","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.945706","article-title":"Comparative immunogenicity of an mRNA\/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques","volume":"13","author":"Valentin","year":"2022","journal-title":"Front Immunol"},{"key":"B202","article-title":"Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients","volume":"19","author":"Levy","year":"2005","journal-title":"AIDS"},{"key":"B203","article-title":"Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection","volume":"11","author":"Jones","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"B204","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/s41467-025-57284-w","article-title":"Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial","volume":"16","author":"Bailon","year":"2025","journal-title":"Nat Commun"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11111663","article-title":"Vaccination with an HIV T-cell immunogen (HTI) using DNA primes followed by a chAdOx1-MVA boost is immunogenic in gut microbiota-depleted mice despite low IL-22 serum levels","volume":"11","author":"Elizalde-Torrent","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-023-00410-4","article-title":"Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates","volume":"31","author":"Burdo","year":"2024","journal-title":"Gene Ther"},{"key":"B207","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12977-022-00600-9","article-title":"Repression of HIV-1 reactivation mediated by CRISPR\/dCas9-KRAB in lymphoid and myeloid cell models","volume":"19","author":"da Costa","year":"2022","journal-title":"Retrovirology"},{"key":"B208","doi-asserted-by":"publisher","first-page":"4979","DOI":"10.1038\/s41467-025-60001-2","article-title":"Efficient mRNA delivery to resting T cells to reverse HIV latency","volume":"16","author":"Cevaal","year":"2025","journal-title":"Nat Commun"},{"key":"B209","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20411\/pai.v1i1.100","article-title":"Defining HIV and SIV reservoirs in lymphoid tissues","volume":"1","author":"Deleage","year":"2016","journal-title":"Pathog Immun"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat Med"},{"key":"B211","unstructured":"Kennedy\n              W\n            \n          \n          Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART\n          \n          2025"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1300662","article-title":"Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV","volume":"370","author":"Tebas","year":"2014","journal-title":"N Engl J Med"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.000139","article-title":"Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR\/Cas9","volume":"96","author":"Li","year":"2015","journal-title":"J Gen Virol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv469","article-title":"mRNA transfection of a novel TAL effector nuclease (TALEN) facilitates efficient knockout of HIV co-receptor CCR5","volume":"43","author":"Mock","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2022.01.012","article-title":"CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice","volume":"24","author":"Li","year":"2022","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.141502","article-title":"Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques","volume":"6","author":"Barber-Axthelm","year":"2021","journal-title":"JCI Insight"},{"key":"B217","doi-asserted-by":"publisher","first-page":"e1009831","DOI":"10.1371\/journal.ppat.1009831","article-title":"CAR\/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection","volume":"18","author":"Pampusch","year":"2022","journal-title":"PloS Pathog"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/d41591-023-00042-6","article-title":"First two patients receive CAR T cell therapy for HIV","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2017.09.040","article-title":"Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer\u2019s patch uptake","volume":"532","author":"Bachhav","year":"2017","journal-title":"Int J Pharm"},{"key":"B220","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3390\/pharmaceutics16030431","article-title":"Targeting the gut: A systematic review of specific drug nanocarriers","volume":"16","author":"Garbati","year":"2024","journal-title":"Pharmaceutics"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2015.02.010","article-title":"Chitosan-catechol: a polymer with long-lasting mucoadhesive properties","volume":"52","author":"Kim","year":"2015","journal-title":"Biomaterials"},{"key":"B222","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1208\/s12249-018-1262-2","article-title":"Active targeting of drugs and bioactive molecules via oral administration by ligand-conjugated lipidic nanocarriers: recent advances","volume":"20","author":"Shreya","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"B223","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/nnm-2022-0248","article-title":"Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles","volume":"18","author":"Asl","year":"2023","journal-title":"Nanomed (Lond)"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S502833","article-title":"Localized drug delivery in different gastrointestinal cancers: navigating challenges and advancing nanotechnological solutions","volume":"20","author":"Hasan","year":"2025","journal-title":"Int J Nanomed"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1039\/D2BM01649D","article-title":"Antiviral supramolecular polymeric hydrogels by self-assembly of tenofovir-bearing peptide amphiphiles","volume":"11","author":"Monroe","year":"2023","journal-title":"Biomater Sci"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2012.01.029","article-title":"The mucoadhesive and gastroretentive properties of hydrophobin-coated porous silicon nanoparticle oral drug delivery systems","volume":"33","author":"Sarparanta","year":"2012","journal-title":"Biomaterials"},{"key":"B227","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4103\/0975-7406.76478","article-title":"Mucoadhesive drug delivery systems","volume":"3","author":"Shaikh","year":"2011","journal-title":"J Pharm Bioallied Sci"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00382","article-title":"Exploring peyer\u2019s patch uptake as a strategy for targeted lung delivery of polymeric rifampicin nanoparticles","volume":"15","author":"Bachhav","year":"2018","journal-title":"Mol Pharm"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.10.006","article-title":"Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development","volume":"340","author":"Singh","year":"2021","journal-title":"J Control Release"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.708806","article-title":"Antibody conjugates for targeted therapy against HIV-1 as an emerging tool for HIV-1 cure","volume":"12","author":"Umotoy","year":"2021","journal-title":"Front Immunol"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2020.06.019","article-title":"Drug delivery system targeting CD4(+) T cells for HIV-1 latency reactivation towards the viral eradication","volume":"109","author":"Jaimalai","year":"2020","journal-title":"J Pharm Sci"},{"key":"B233","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/138920012798356899","article-title":"The ligand nanoparticle conjugation approach for targeted cancer therapy","volume":"13","author":"Karra","year":"2012","journal-title":"Curr Drug Metab"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T05:31:49Z","timestamp":1758173509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1650852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":233,"alternative-id":["10.3389\/fimmu.2025.1650852"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1650852","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"article-number":"1650852"}}